

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)



(10) International Publication Number
WO 2021/127200 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 47/68* (2017.01)

(21) International Application Number:
PCT/US2020/065642

(22) International Filing Date:
17 December 2020 (17.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/950,434 19 December 2019 (19.12.2019) US

(71) Applicant: **NGM BIOPHARMACEUTICALS, INC.**
[US/US]; 333 Oyster Point Boulevard, South San Francisco,
California 94080 (US).

(72) Inventors: **CRAWLEY, Suzanne Christine**; 333 Oyster
Point Boulevard, South San Francisco, California 94080
(US). **HSU, Jer-Yuan**; 333 Oyster Point Boulevard, South
San Francisco, California 94080 (US). **KAPLAN, Daniel
David**; 333 Oyster Point Boulevard, South San Francisco,
California 94080 (US). **LI, Betty Chan**; 333 Oyster Point
Boulevard, South San Francisco, California 94080 (US).
LIN, Vicky Yi-Bing; 333 Oyster Point Boulevard, South
San Francisco, California 94080 (US). **MALMERSJÖ,
Seth**; 333 Oyster Point Boulevard, South San Francisco,
California 94080 (US). **PAAVOLA, Kevin James**; 333
Oyster Point Boulevard, South San Francisco, California
94080 (US). **RODA, Julie Michelle**; 333 Oyster Point
Boulevard, South San Francisco, California 94080 (US).
WANG, Yan; 333 Oyster Point Boulevard, South San Francisco,
California 94080 (US).

(74) Agent: **GUPTA, Meghana** et al.; Fish & Richardson P.C.,
P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2021/127200 A1

(54) Title: ILT3-BINDING AGENTS AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind ILT3, including human ILT3, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.